Ginkgo Bioworks (DNA) Q1 Revenues Beat; Guides Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Ginkgo Bioworks Reports First Quarter 2022 Financial Results
May 16, 2022 4:01 PM EDT$168 million of Total revenue in Q1 2022, representing an increase of 282% over Q1 2021
11 new Cell Programs added in Q1 2022, representing 175% growth over Q1 2021
Increasing full year guidance for Total revenue from $325Â $340 million to $375 $390 million, reiterating Foundry revenue guidance and increasing Biosecurity revenue guidance
Recently announced plans to expand platform capabilities in agricultural biologicals through a series of M&A transactions and flagship collaboration with Bayer
$1.5 billion cash balance provides meaningful multi-year runway as we drive towards... More
